City page
Copenhagen biotech and pharma directory
Copenhagen anchors Medicon Valley — the cross-border life-sciences cluster connecting Denmark and southern Sweden — and is home to global pharma majors Novo Nordisk (Bagsværd, world's largest GLP-1/insulin manufacturer) and Lundbeck (CNS therapeutics). Anchor mid-cap biotech: Genmab (antibody platform, the country's largest pure biotech), Zealand Pharma (peptide therapeutics), Bavarian Nordic (vaccines). The BioInnovation Institute incubator runs out of Copenhagen.
Where does this city read strongest?
Therapeutics (8), Cluster (2), and Diagnostics (2). Most visible records: Adcendo ApS, Fuse Vectors ApS, and Galecto, Inc..
Which standards and public evidence are already visible?
GMP (2) and FDA-Inspected (1). Latest review: 24 April 2026. Review cycle: April 2026.
Why does this city matter?
This page brings visible companies and infrastructure records into one practical view of Copenhagen.
By category
Copenhagen by category
Jump into a category page filtered to this country only.
Full list
Copenhagen biotech and pharma directory
14 city records currently match the active filter.
Current review cycle
Adcendo ApS
CopenhagenDenmarkTherapeutics
Copenhagen clinical-stage antibody-drug conjugate biotech with a first- and best-in-class pipeline led by ADCE-D01, a uPARAP-targeted ADC with FDA Fast Track designation for soft-tissue sarcoma.
- Lead
- Michael PehlChief Executive Officer
- Scale
- Clinical-stage ADC development
Current review cycle
Fuse Vectors ApS
CopenhagenDenmarkBiotech
Copenhagen gene-therapy platform biotech developing a cell-free viral vector manufacturing system for scalable AAV production, with pre-seed backing from HCVC and BII and an active R&D site in Leiden, Netherlands.
- Lead
- Jordan TurnbullCo-Chief Executive Officer and Co-Founder
- Scale
- Platform R&D to early process demonstration
Current review cycle
Galecto, Inc.
CopenhagenDenmarkTherapeutics
Nasdaq-listed clinical-stage biotech (GLTO) with Copenhagen operating headquarters, developing small-molecule galectin-3 and LOXL2 inhibitors for fibrosis, oncology, and inflammation.
- Lead
- Hans SchambyeChief Executive Officer
- Scale
- Clinical-stage small-molecule development
Current review cycle
GLX Analytix ApS
CopenhagenDenmarkDiagnostics
Copenhagen glycomics IVD startup building AI-augmented GlycA and GlycB-class biomarker tests for neurodegenerative and autoimmune disease diagnostics and monitoring.
- Lead
- Brian DellavalleChief Executive Officer and Founder
- Scale
- Diagnostics platform development
Current review cycle
Hoba Therapeutics ApS
CopenhagenDenmarkTherapeutics
Copenhagen clinical-stage neuroscience biotech developing non-opioid chronic neuropathic pain and sensorineural hearing loss therapeutics, with lead candidate HB-086 targeting the peripheral nervous system.
- Lead
- Torsten M. MadsenChief Executive Officer
- Scale
- Early clinical-stage biotech
Current review cycle
Acesion Pharma
CopenhagenDenmarkTherapeutics
Copenhagen biotech company developing novel therapies for atrial fibrillation and other cardiac arrhythmias from a Danish clinical-development base.
- Lead
- Anders Haahr MathiesenChief Executive Officer
- Scale
- Clinical-stage therapeutics platform
Current review cycle
2cureX
CopenhagenDenmarkDiagnostics
Copenhagen precision-oncology diagnostics company commercializing functional drug-sensitivity testing to guide personalized cancer treatment decisions.
- Lead
- Ole ThastrupCEO
- Scale
- Diagnostics platform
Current review cycle
IO Biotech
CopenhagenDenmarkTherapeutics
Copenhagen immuno-oncology company developing immune-modulating cancer therapeutics and clinical-stage vaccine-based programs from Denmark.
- Lead
- Mai-Britt ZoccaCEO
- Scale
- Clinical-stage therapeutics platform
Current review cycle
BioInnovation Institute
CopenhagenDenmarkCluster
Copenhagen life-sciences venture-building and laboratory platform supporting company creation, incubation, translational research, and startup infrastructure across therapeutics, biotech tools, and planetary-health programs.
- Lead
- Jens NielsenCEO
- Scale
- Multi-company venture-building and laboratory platform
Current review cycle
Statens Serum Institut
CopenhagenDenmarkResearch
Copenhagen national public-health institute operating infectious-disease surveillance, reference diagnostics, preparedness functions, and laboratory infrastructure central to Denmark's life-sciences and health-security system.
- Lead
- Henrik UllumPresident and CEO
- Scale
- National-scale public-health and diagnostic infrastructure
Current review cycle
Medicon Valley Alliance
CopenhagenDenmarkCluster
Cross-border Danish-Swedish life-science cluster alliance coordinating membership, project development, and infrastructure collaboration across Medicon Valley.
- Lead
- Anette SteenbergChief Executive Officer
- Scale
- Danish-Swedish cluster coordination hub
Current review cycle
Zealand Pharma
CopenhagenDenmarkTherapeutics
Copenhagen-area peptide therapeutics company focused on obesity, metabolic disease, and specialty indications through discovery and late-stage development.
- Lead
- Adam SteensbergPresident and Chief Executive Officer
- Scale
- Global Biopharma
Current review cycle
Genmab A/S
CopenhagenDenmarkTherapeutics
Copenhagen antibody-therapeutics headquarters running Genmab's platform-engineering, translational science, and late-stage oncology execution from its Valby base.
- Lead
- Jan van de WinkelPresident and Chief Executive Officer
- Scale
- Global Biopharma
Current review cycle
H. Lundbeck A/S
CopenhagenDenmarkTherapeutics
Copenhagen-area neuroscience therapeutics company combining brain-disease R&D, regulated pharmaceutical supply, and global commercial operations.
- Lead
- Charl van ZylPresident and CEO
- Scale
- Global Supply
FAQ
Frequently asked questions
- What is Medicon Valley?
- Medicon Valley is the cross-border biotech cluster connecting Copenhagen (Denmark) with Lund and Malmö (southern Sweden), spanning the Øresund region. It's one of Europe's strongest life-sciences hubs, anchored by Novo Nordisk and Lundbeck on the Danish side and Lund University, AstraZeneca legacy, and BioArctic on the Swedish side.
- What companies are in Copenhagen biotech?
- Novo Nordisk (Bagsværd, GLP-1/insulin global leader), Lundbeck (CNS therapeutics global), Genmab (antibody platform — the country's largest pure biotech), Zealand Pharma (peptides — GLP-1, glucagon), Bavarian Nordic (vaccines), plus a long tail of mid-cap and emerging biotech anchored by the BioInnovation Institute incubator.
- What sectors are strongest in Copenhagen biotech?
- Copenhagen is strongest in cardiometabolic therapeutics (Novo Nordisk's GLP-1, insulin, glucagon dominance), CNS / neuroscience (Lundbeck), antibody and ADC platforms (Genmab), peptide chemistry (Zealand Pharma), vaccines (Bavarian Nordic), and the broader BioInnovation Institute incubator pipeline. FDA-inspected manufacturing is widespread.
Related briefs
Briefs that mention Copenhagen
European mRNA & Immunotherapy Supply Chain 2026
Where the European mRNA, vaccine, and immunotherapy supply chain actually sits in 2026 — BioNTech, CureVac, IDT Biologika, AGC Biologics, BioSpring, Bachem, plus the Nordic vaccine layer — and how the pieces fit.
Open briefViral Vector CDMO Europe 2026: AAV, Adenovirus, Lentivirus
Where to manufacture viral vectors in Europe in 2026 — FinVector, Kuopio Center for Gene and Cell Therapy, 3PBIOVIAN, Fuse Vectors, IDT Biologika — and how the European viral vector CDMO layer is structured.
Open briefNordic Biotech Landscape 2026: Denmark, Sweden, Finland, Norway
A practical map of the Nordic biotech and pharma landscape in 2026 — 124 operators across Denmark, Sweden, Finland, and Norway, anchored by Novo Nordisk, Genmab, Lundbeck, AstraZeneca Gothenburg, Bavarian Nordic, Orion, and a dense Medicon Valley + Karolinska cluster layer.
Open briefNext step
Read the city, then widen the view.
Use country and regional pages for wider context, and the company suggestion form for new candidate records.